CLEVELAND — A groundbreaking randomized clinical trial led by Chair of Radiation Oncology Daniel Spratt at University ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...

Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a ...

This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." ...